ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 132,32
-0,78%
Dow Jones
39 806,77
-0,49%
DAX
18 688,10
-0,42%
Brent Oil
82,905
-0,75%
Bitcoin
71 005,02
-0,62%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Moleculin Biotech Inc (MBRX)

  7. Moleculin Biotech Inc (MBRX) Actualités

MBRX

Moleculin Biotech (MBRX)

Moleculin Biotech Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MBRX
DateHeureSourceTitreSymboleSociété
16/05/202414h32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
16/05/202414h32PR Newswire (US)Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid CongressNASDAQ:MBRXMoleculin Biotech Inc
15/05/202414h38PR Newswire (US)Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)NASDAQ:MBRXMoleculin Biotech Inc
13/05/202416h53Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:MBRXMoleculin Biotech Inc
13/05/202413h30PR Newswire (US)Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:MBRXMoleculin Biotech Inc
10/05/202422h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MBRXMoleculin Biotech Inc
09/05/202414h30PR Newswire (US)Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for AnnamycinNASDAQ:MBRXMoleculin Biotech Inc
08/05/202414h45PR Newswire (US)Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and WebcastNASDAQ:MBRXMoleculin Biotech Inc
07/05/202414h55PR Newswire (US)Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject DataNASDAQ:MBRXMoleculin Biotech Inc
02/05/202415h00PR Newswire (US)Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024NASDAQ:MBRXMoleculin Biotech Inc
01/05/202414h50PR Newswire (US)Moleculin Announces Formation of Scientific Advisory Board to Support Development of AnnamycinNASDAQ:MBRXMoleculin Biotech Inc
18/04/202414h30PR Newswire (US)European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)NASDAQ:MBRXMoleculin Biotech Inc
10/04/202414h30PR Newswire (US)Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic PropertiesNASDAQ:MBRXMoleculin Biotech Inc
28/03/202415h45PR Newswire (US)Moleculin to Present at the MedInvest Biotech & Pharma Investor ConferenceNASDAQ:MBRXMoleculin Biotech Inc
27/03/202414h25PR Newswire (US)Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin OpportunityNASDAQ:MBRXMoleculin Biotech Inc
27/03/202414h05PR Newswire (US)Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AMLNASDAQ:MBRXMoleculin Biotech Inc
25/03/202412h30PR Newswire (US)Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML TrialNASDAQ:MBRXMoleculin Biotech Inc
22/03/202421h05PR Newswire (US)Moleculin Reports Full Year 2023 Financial ResultsNASDAQ:MBRXMoleculin Biotech Inc
20/03/202412h30PR Newswire (US)Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and WebcastNASDAQ:MBRXMoleculin Biotech Inc
20/03/202412h15IH Market NewsJPMorgan boosts dividends, Chipotle unveils 50:1 stock split, and Latest NewsNASDAQ:MBRXMoleculin Biotech Inc
19/03/202421h30PR Newswire (US)Moleculin Announces Reverse Stock SplitNASDAQ:MBRXMoleculin Biotech Inc
12/03/202414h05PR Newswire (US)Moleculin to Present at the 36th Annual ROTH ConferenceNASDAQ:MBRXMoleculin Biotech Inc
16/02/202423h19Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:MBRXMoleculin Biotech Inc
13/02/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MBRXMoleculin Biotech Inc
02/02/202423h05Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:MBRXMoleculin Biotech Inc
24/01/202414h50PR Newswire (US)Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3NASDAQ:MBRXMoleculin Biotech Inc
16/01/202423h00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:MBRXMoleculin Biotech Inc
05/01/202423h15Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:MBRXMoleculin Biotech Inc
27/12/202313h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MBRXMoleculin Biotech Inc
22/12/202323h00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MBRXMoleculin Biotech Inc
 Showing the most relevant articles for your search:NASDAQ:MBRX

Dernières Valeurs Consultées

UNSW3
KUMAETH
Kuma Inu
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés